Research ArticleCancer Immunotherapy

GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells

See allHide authors and affiliations

Science Translational Medicine  27 Mar 2019:
Vol. 11, Issue 485, eaau7746
DOI: 10.1126/scitranslmed.aau7746

CARs to drive away multiple myeloma

Chimeric antigen receptor (CAR) T cells, a type of cell-based immunotherapy, have shown some promising results in multiple myeloma, a bone marrow cancer. These earlier CAR T cells targeted a protein called B cell maturation antigen, but some patients’ cancer cells expressed little to none of this antigen and were therefore resistant to the CAR T cells. Smith et al. identified another target antigen for multiple myeloma, called GPRC5D. The authors demonstrated that CAR T cells against GPRC5D are effective in mouse models, even those with tumors that are resistant to the earlier CARs, and they are safe in mice and primates.

View Full Text

Stay Connected to Science Translational Medicine